Company intelligence / Profile preview
Biomunex Pharmaceuticals
Paris, Île-de-France?, Francebiomunex.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Biomunex is pioneering a disruptive immuno-oncology approach by developing bispecific antibodies that redirect MAIT cells to kill cancer cells. Their flagship program BMX500 uses the BiXAb® platform to engage this unique T-cell subpopulation, aiming to overcome limitations of classical CD3-based T-cell engagers such as cytokine release syndrome and local immunosuppression. The company has presented promising preclinical results at major conferences like AACR and is advancing towards clinical trials[2][4][6].
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesMulti-specific antibodiesMAIT cell engagers (a novel T-cell engager modality)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Licensing agreement with Sanofi for generation and optimization of bi-and multi-specific antibody therapeutics.Collaboration with Institut Curie for discovery/development of MAIT cell redirection technology.Collaboration/licensing deal with Onward Therapeutics.[5][6]
Beyond the preview
Go deeper on Biomunex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomunex Pharmaceuticals.